Nilotinib (AMN-107)

製品コードS1033

カスタマーフィードバック(5)

  • Ba/F3-p210T315I cells were treated with indicated concentrations of nilotinib with or without PDMP for 24 h. Apoptosis was determined as in A. Data are shown as percentage of sub-G1 for apoptosis in triplicate cultures. *P<0.05.

    FASEB J 2011 25, 3661-3673. Nilotinib (AMN-107) purchased from Selleck.

    Effect of nilotinib on Bcr-Abl kinase activity in ABCB1- and ABCG2- overexpressing CD34+CD38- cells. K562 parental cells and CD34+CD38- subpopulation isolated from K562 cells were treated with nilotinib at 0.01, 0.1 and 1.0 umol/L for 12 h. Equal amount of protein was loaded for western blot analysis as described in the Experimental section. The experiments were repeated at least three times independently, and a representative experiment is shown.

    Molecules 2014 19, 3356-75. Nilotinib (AMN-107) purchased from Selleck.

  •  

    Inhibition of thymidine (a and b) and cytarabine (c and d) uptake with nilotinib. The legend is similar to Fig. 1, except that imatinib was replaced by nilotinib.

    Leukemia Res 2012 36, 1311-1314. Nilotinib (AMN-107) purchased from Selleck.

    Nilotinib up-regulates the ERK survival signal in prostate cancer cells. (B and C) Immunoblot analyses of DU-145 cells (B) or DU-145 cells in comparison with LNCaP and PC-3 cells (C) treated with nilotinib for the expression of phospho-ERK1/2 T202/Y204 and total ERK. Immunoblot for GAPDH is shown as a loading control.

    Urol Oncol 2014 0.1016/j.urolonc.2014.06.001. Nilotinib (AMN-107) purchased from Selleck.

  • Immunohistochemical staining of xenografted DU-145 cells after 21 days of treatment with 75 mg/kg/d of nilotinib for phospho-ERK1/2 T202/Y204 expression. It can be noted that tumors explanted from vehicle-treated mice showed mostly positivity at the tumor periphery, whereas tumors explanted from nilotinib-treated mice showed a more evenly distributed phospho-ERK immunostaining (left panels). Quantification of phospho-ERK-positive DU-145 xenografts explanted after 21 days of treatment. Mean and standard errors of positive cells per high-power field (HPF; x40) from at least 3 tumors are given (right panel).

    Urol Oncol 2014 0.1016/j.urolonc.2014.06.001. Nilotinib (AMN-107) purchased from Selleck.

製品安全説明書

Bcr-Abl阻害剤の選択性比較

生物活性

製品説明 Nilotinib (AMN-107)は一種のBcr-Abl阻害剤で、マウス類骨髄前駆細胞の中にIC50値が30 nM以下です。
特性 A selective inhibitor of native and mutant Bcr-Abl.
靶点
Bcr-Abl [1]
(Murine myeloid progenitor cells)
<30 nM
In vitro試験

Nilotinib inhibits proliferation, migration, and actin filament formation, as well as the expression of α-SMA and collagen in activated HSCs. Nilotinib induces apoptosis of HSCs, which is correlated with reduced bcl-2 expression, increases p53 expression, cleavage of PARP, as well as increases expression of PPARγ and TRAIL-R. Nilotinib also induces cell cycle arrest, accompanied by increased expression of p27 and downregulation of cyclin D1. Interestingly, Nilotinib not only inhibits activation of PDGFR, but also TGFRII through Src. Nilotinib significantly inhibits PDGF and TGFβ-simulated phosphorylation of ERK and Akt. Furthermore, PDGF- and TGFβ-activated phosphorylated form(s) of Abl in human HSCs are inhibited by Nilotinib. [2] Nilotinib inhibits most imatinib-resistant Bcr-Abl mutations, except for T315I. [3] Nilotinib inhibits PDGF-DD-mediated ERK1/2 activation, basal and PDGF-DD-mediated activation of PDGFRβ and Akt, and schwannoma proliferation. Nilotinib is more potent than imatinib, exerting its maximal inhibitory effect at concentrations lower than steady-state trough plasma levels. [4] Nilotinib also significantly reduces the expression levels of the genes for TGF-β1 and platelet-derived growth factor (PDGF). Nilotinib treatment also significantly inhibits the PDGF-induced proliferation of lung fibroblasts. [5] Nilotinib inhibits the proliferation of Ba/F3 cells expressing p210- and p190-Bcr-Abl, or K562 and Ku-812F cells with IC50 values ≤12 nM. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell NHzV[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwMECwNVQ1KM7:TR?= NFXBUm1USU6JRWK=
KU812 Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7nZpdKSzVyPUCuNFAzPDhizszN M3rNN3NCVkeHUh?=
EM-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTVNohLUUN3ME2wMlAxPDFizszN M33BWHNCVkeHUh?=
LAMA-84 NVz5ZoZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\mRoNwUUN3ME2wMlAxPDlizszN M3PQc3NCVkeHUh?=
MEG-01 MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwMEC4Nlgh|ryP M{fOZ3NCVkeHUh?=
BV-173 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXyOFlKSzVyPUCuNFExQDlizszN MnLqV2FPT0WU
KASUMI-1 M3\NVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzveFlPUUN3ME2wMlAzPDF|IN88US=> NGHNOXFUSU6JRWK=
NB7 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFH3fpNKSzVyPUCuNVM1OzlizszN MUTTRW5ITVJ?
BHT-101 NHr0O2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHQTWM2OD1yLk[0NlY{KM7:TR?= MVzTRW5ITVJ?
CGTH-W-1 NVmyN3o3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Tze2lEPTB;MD62OFg4KM7:TR?= NFrjOmdUSU6JRWK=
HMV-II NGXnU2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHuVJpkUUN3ME2wMlc1QDd2IN88US=> M1zCRnNCVkeHUh?=
NKM-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwOUCxOUDPxE1? NWTHV4Q1W0GQR1XS
LB2241-RCC NVrXNIg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfRcHlKSzVyPUGuNFIzOjhizszN MVPTRW5ITVJ?
NCI-H1703 M4C0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\NUHJFUUN3ME2xMlE5QDdizszN NU\OSnFlW0GQR1XS
BE-13 NHjFbpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTFwMke0NVYh|ryP MYfTRW5ITVJ?
ACN NXXubJU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTFwNUWwO|ch|ryP MoX3V2FPT0WU
A204 M2HvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTFwNUeyNFUh|ryP MoDtV2FPT0WU
HOP-62 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PJdGlEPTB;MT64NlA4PyEQvF2= NUnkWm9PW0GQR1XS
H9 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTJwN{O3PVMh|ryP NH7UUJhUSU6JRWK=
HCC1806 NWC2XYJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;xTWM2OD1{Lke0N|I4KM7:TR?= MWHTRW5ITVJ?
NOS-1 Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjKdIZuUUN3ME2yMlg4OTB{IN88US=> NEjmPIhUSU6JRWK=
RS4-11 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rOcmlEPTB;Mj65NFYzOyEQvF2= M1y4enNCVkeHUh?=
JAR MnTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTJwOUKwPFQh|ryP NEDtSIRUSU6JRWK=
T98G MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXmUYVXUUN3ME2zMlAyOzF|IN88US=> M2K1NnNCVkeHUh?=
NCI-SNU-1 NGPN[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;LbYdKSzVyPUOuOFAxQTJizszN M4rCfnNCVkeHUh?=
SK-MEL-1 NG\BN2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTNwNEOwNlkh|ryP M2n6UnNCVkeHUh?=
L-363 NVfPTXVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfld3pKSzVyPUOuOlEyODdizszN NGHMRoZUSU6JRWK=
SW982 NX\PfFhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7Sc2ZwUUN3ME2zMlY1OTZ7IN88US=> M2HxdXNCVkeHUh?=
HT-1080 NVH0coxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnMem84UUN3ME2zMlkyPzd3IN88US=> NUPH[JpNW0GQR1XS
G-402 M1i2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;nTWM2OD12LkOxNlA{KM7:TR?= M2XXfXNCVkeHUh?=
HOS NILuUWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrEW3NqUUN3ME20MlgxOjh{IN88US=> NHi4U5FUSU6JRWK=
SK-NEP-1 NFTNfFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGj2PZZKSzVyPUSuPFMyQTFizszN NWnDfYtSW0GQR1XS
HAL-01 M1:xTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfLfpdKSzVyPUSuPFgzPDJizszN MljNV2FPT0WU
SBC-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrMS|hKSzVyPUSuPVA6ODdizszN NWjNOGVxW0GQR1XS
CTV-1 NGXObVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4SyNmlEPTB;NT60PFk{QCEQvF2= M4riUXNCVkeHUh?=
LCLC-103H MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTVwN{e0O|Eh|ryP MVTTRW5ITVJ?
RVH-421 MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXL2UGQ3UUN3ME21Mlc4PTN4IN88US=> NVnWdGJXW0GQR1XS
K-562 NITNcmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3K0TGlEPTB;NT65NFM3KM7:TR?= NGGzOZdUSU6JRWK=
CAL-33 M1nSW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HpUmlEPTB;Nj6zNVM2QSEQvF2= MYjTRW5ITVJ?
MDA-MB-361 Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTZwM{O2PVkh|ryP M4rTUnNCVkeHUh?=
IGROV-1 MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILofWJKSzVyPU[uOFcyQTFizszN MWjTRW5ITVJ?
NY NHPXWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml6xTWM2OD14LkWzOVk6KM7:TR?= M{[2RXNCVkeHUh?=
Ramos-2G6-4C10 M2\EUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HpU2lEPTB;Nj62Olk{OSEQvF2= MoL3V2FPT0WU
HuO9 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nuTWlEPTB;Nj63N|k3PCEQvF2= MnHEV2FPT0WU
MS-1 MkC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHVTWM2OD15LkGxPVU{KM7:TR?= M1fLT3NCVkeHUh?=
RPMI-8226 Ml7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3aTWM2OD15LkK4Nlg4KM7:TR?= M4HkRnNCVkeHUh?=
HDLM-2 M132VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDwTWM2OD15LkSwNVQ6KM7:TR?= NX;hSW5kW0GQR1XS
D-566MG NULKOXpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\wWGlEPTB;Nz60O|E2PSEQvF2= M4DpTHNCVkeHUh?=
SK-MEL-24 NFXKbHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTdwNkOzPVIh|ryP MUXTRW5ITVJ?
COLO-679 Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP5TWM2OD15Lkm4OlcyKM7:TR?= M3SySHNCVkeHUh?=
EW-13 NUGzZpd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3P3VWlEPTB;OD6zNlA2PCEQvF2= MoHmV2FPT0WU
A388 NGrLbldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLq[mxKSzVyPUiuN|g1QDFizszN M{\vbnNCVkeHUh?=
UM-UC-3 NHnHe4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\MdFZOUUN3ME24MlQ{QTV4IN88US=> MojyV2FPT0WU
NUGC-3 M2PNdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vVd2lEPTB;OD61N|U5OiEQvF2= NH\p[YJUSU6JRWK=
COLO-668 NEDYZmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRThwNUm0PVEh|ryP MlTVV2FPT0WU
MOLT-4 MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRThwNkKzOVMh|ryP MULTRW5ITVJ?
D-423MG M1PrXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkj6TWM2OD16LkizO|U3KM7:TR?= NGDyfIFUSU6JRWK=
CTB-1 NY\IOXFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnq0TWM2OD16Lki3NVI5KM7:TR?= MmC2V2FPT0WU
BCPAP NVWxb|JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXn5b3JTUUN3ME25MlAzPTZ{IN88US=> NF3aUnRUSU6JRWK=
GCT MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnjTWM2OD17LkC5PFMyKM7:TR?= NHSyOYJUSU6JRWK=
ACHN MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\ETWM2OD17LkKzOlMzKM7:TR?= NYe1eGxbW0GQR1XS
KYSE-520 Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1S5cmlEPTB;OT6zN|Q5OiEQvF2= Mn73V2FPT0WU
LB771-HNC NFv4c5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjoVmVLUUN3ME25Mlc3PDl5IN88US=> MnjwV2FPT0WU
MLMA NIrWU|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTFyLkCxN|Ih|ryP MYTTRW5ITVJ?
HEC-1 NXL6ZXFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjqTWM2OD1zMD6yPFA1KM7:TR?= MU\TRW5ITVJ?
HL-60 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LHPGlEPTB;MUCuOlg2OyEQvF2= M3v1Z3NCVkeHUh?=
A101D NEf1bZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfQNJpKSzVyPUGwMlg6OjNizszN Mk\HV2FPT0WU
A2058 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f6TmlEPTB;MUCuPVI1PSEQvF2= MnHRV2FPT0WU
KARPAS-45 NXrucWtzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrvNG9KSzVyPUGxMlA3OzVizszN MUfTRW5ITVJ?
697 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moe4TWM2OD1zMT6yNVAyKM7:TR?= M3jYXnNCVkeHUh?=
NCI-N87 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFf0e2hKSzVyPUGxMlc4OzFizszN M4HpeXNCVkeHUh?=
DSH1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWW5dItCUUN3ME2xNU44QTV|IN88US=> M2PlR3NCVkeHUh?=
HLE NUXP[2Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jlNmlEPTB;MUGuPFg{QSEQvF2= NXyyUYNXW0GQR1XS
NCI-H720 NWT1[mdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTF{Lk[4NFEh|ryP NGrsPIpUSU6JRWK=
EW-3 NFSzfmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTF{LkmzNFch|ryP MmXTV2FPT0WU
AGS Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGriXWxKSzVyPUGzMlA{PTFizszN NEPzOJVUSU6JRWK=
ES5 Mk\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\VTWM2OD1zMz6wOVEzKM7:TR?= NV\2[mxrW0GQR1XS
DB NIHJT45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTF|LkOyOVYh|ryP NGrKZ2pUSU6JRWK=
A4-Fuk M1z4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlziTWM2OD1zMz60NVAzKM7:TR?= M{LiW3NCVkeHUh?=
A427 Mnz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXvTWM2OD1zMz60PVczKM7:TR?= NH;0SXZUSU6JRWK=
MN-60 NV\aVXlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTnXnl1UUN3ME2xN{42QDR|IN88US=> MkSwV2FPT0WU
HCC2218 MojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzCTWM2OD1zMz61PFU3KM7:TR?= NE\t[GhUSU6JRWK=
MV-4-11 MnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXm3fVhLUUN3ME2xN{45OTN5IN88US=> NH73dlBUSU6JRWK=
GI-1 Mn\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3FRoRKSzVyPUG0MlEyQDRizszN MnXCV2FPT0WU
JVM-3 M2LkZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjxeIdPUUN3ME2xOE4zPjV4IN88US=> NYjPeHFOW0GQR1XS
NCI-H2029 MoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvNW49MUUN3ME2xOE4zPzJ5IN88US=> NWLSenl4W0GQR1XS
TE-12 M3rtOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXSeXBKSzVyPUG0MlYxPDZizszN NFy2V4xUSU6JRWK=
WM-115 M{HiVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3GTHJKSzVyPUG1MlU3QDNizszN NFvXU|VUSU6JRWK=
BB65-RCC M1:1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGe2U5FKSzVyPUG2MlAzPDFizszN MVTTRW5ITVJ?
NCI-H1693 NF7lcndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnxRWJ[UUN3ME2xOk4{QDB{IN88US=> NFjReFZUSU6JRWK=
KARPAS-299 M1\RWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmKyTWM2OD1zNj62NlA{KM7:TR?= NVPZZmYzW0GQR1XS
UACC-257 M4DYUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\SOWlEPTB;MUeuNFU5OiEQvF2= M33VVnNCVkeHUh?=
RKO NXG4SVdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2flcWlEPTB;MUeuOlQ{OyEQvF2= NIjhVHVUSU6JRWK=
HT-29 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLnTWM2OD1zNz63PFg6KM7:TR?= MmfZV2FPT0WU
ES7 NHvl[2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{GwWWlEPTB;MUiuNVEzOiEQvF2= NV3sR5hkW0GQR1XS
DEL NWLSd|dNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\zemdZUUN3ME2xPE4{OTd{IN88US=> NXvWdIlNW0GQR1XS
BT-549 Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTF6LkSwPVIh|ryP MWrTRW5ITVJ?
NCI-H1755 M2S1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXG4XY9kUUN3ME2xPE42PzJ|IN88US=> Mkf6V2FPT0WU
HCE-T MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDyTWM2OD1zOD64N|QyKM7:TR?= MWLTRW5ITVJ?
LU-139 NXrSdW5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTF7LkC0OVgh|ryP NF6zPWNUSU6JRWK=
ECC10 Ml7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTF7LkK0O|Uh|ryP MVnTRW5ITVJ?
769-P NEjMdoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEm2fYtKSzVyPUG5MlY{OzVizszN NH7oPItUSU6JRWK=
BALL-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1H4T2lEPTB;MUmuOlc4PSEQvF2= M1zvTXNCVkeHUh?=
LXF-289 NV20ZWZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTF7Lki5O|kh|ryP NGrMXItUSU6JRWK=
TYK-nu MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHvTWM2OD1zOT65N|E2KM7:TR?= MoS3V2FPT0WU
NCI-H630 M1nOVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\2XVlKSzVyPUG5Mlk{PzhizszN MnL4V2FPT0WU
EW-18 M3nLfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHG0SHRKSzVyPUKwMlM5ODJizszN MnPmV2FPT0WU
KYSE-150 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfIO|FDUUN3ME2yNE44ODR5IN88US=> Moq2V2FPT0WU
LOXIMVI MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTZNWx3UUN3ME2yNE44PTh4IN88US=> NInUO2tUSU6JRWK=
HuP-T3 NULNd3NuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHo[mJJUUN3ME2yNU4xQDV{IN88US=> M2XISXNCVkeHUh?=
MFE-280 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTBTWM2OD1{MT61Olc6KM7:TR?= MVLTRW5ITVJ?
SK-OV-3 Mk\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M331WmlEPTB;MkGuPFQxQCEQvF2= M4G5bHNCVkeHUh?=
QIMR-WIL MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTJ{LkC0O|gh|ryP NVzZOHAzW0GQR1XS
NCI-H69 MnXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fpO2lEPTB;MkKuOFI6QSEQvF2= M3X6WnNCVkeHUh?=
TE-5 NVzufWx2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDRNG5nUUN3ME2yNk41QTZ3IN88US=> M3H1eXNCVkeHUh?=
NCI-H1993 M{LBcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\GclJlUUN3ME2yNk41QTdzIN88US=> NFTFTm1USU6JRWK=
NCI-H1092 NEXSXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTJ|LkK4OFMh|ryP M17W[3NCVkeHUh?=
RH-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ixNWlEPTB;MkOuOVM2PyEQvF2= MU\TRW5ITVJ?
DBTRG-05MG MlTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXkdWpKSzVyPUKzMlg1PzJizszN MV;TRW5ITVJ?
Mo-T NXzzNJA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTJ|Lkmg{txO NX\PSHZCW0GQR1XS
HD-MY-Z M131O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NID5eXRKSzVyPUK0MlI{PjJizszN NGjVS2xUSU6JRWK=
NCI-H2342 NXjMTItlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13xXmlEPTB;MkSuOlc3PyEQvF2= NWDQXYl5W0GQR1XS
C32 NFXvZZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zu[mlEPTB;MkSuPVU4PiEQvF2= Mn\ZV2FPT0WU
HTC-C3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DsemlEPTB;MkWuN|U4PyEQvF2= NXPVTmVxW0GQR1XS
NCI-H358 MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnQNXdKSzVyPUK1MlM6PDNizszN MYXTRW5ITVJ?
CAL-85-1 MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LWN2lEPTB;MkWuOFU4PyEQvF2= Mn7OV2FPT0WU
HT-1197 NHvOcppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfEW2hKSzVyPUK1MlU{OTlizszN MXzTRW5ITVJ?
A172 MlKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPMW4lKSzVyPUK1MlcyOzZizszN MVPTRW5ITVJ?
SW1573 NHvQdnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHT3SWJKSzVyPUK1Mlc4QDVizszN MkTzV2FPT0WU
EW-24 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH3TWM2OD1{NT65OlIh|ryP NY\NT4VsW0GQR1XS
SK-MEL-2 NG\RPY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;BN4pUUUN3ME2yOk4xOzF{IN88US=> MV7TRW5ITVJ?
LU-65 NVvwdG1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnW0TWM2OD1{Nj6wOFUzKM7:TR?= M{frSXNCVkeHUh?=
KMOE-2 NETyd4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[3c3lKSzVyPUK2MlA6OTVizszN MXHTRW5ITVJ?
H-EMC-SS MlTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnSU5c5UUN3ME2yOk41OTF2IN88US=> NF\QeJNUSU6JRWK=
H4 NE\zWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJ4LkSyOFMh|ryP MWDTRW5ITVJ?
DU-4475 MofqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\GTWM2OD1{Nz6xPFczKM7:TR?= M4DLcnNCVkeHUh?=
HCT-116 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJ5LkSzOFkh|ryP NF;IOXVUSU6JRWK=
MSTO-211H NVyxcHk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rMO2lEPTB;MkeuOlI2PSEQvF2= NYnBclFkW0GQR1XS
NCI-H292 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrpTWM2OD1{Nz65OlE4KM7:TR?= NEDU[HVUSU6JRWK=
NCI-H446 MmjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJ6LkKxNFUh|ryP MYjTRW5ITVJ?
NCI-H2009 M4nQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rQXmlEPTB;MkmuNVQ{OSEQvF2= MVvTRW5ITVJ?
MHH-ES-1 NVrh[I5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jPfGlEPTB;MkmuN|Y5PSEQvF2= Mk\sV2FPT0WU
TI-73 NULLS3BwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHmTWM2OD1{OT60NFAyKM7:TR?= NEflXmFUSU6JRWK=
NCI-H2228 MnfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTJ7LkS1PEDPxE1? MnS2V2FPT0WU
MHH-PREB-1 NGLCUIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnMcY1KSzVyPUK5MlU2ODVizszN NI\YfI5USU6JRWK=
ChaGo-K-1 NEnvTm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\rTWM2OD1{OT62NFk4KM7:TR?= NYjHS4JlW0GQR1XS
KY821 NID3SXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHeyc|VKSzVyPUK5MlY1OzNizszN NXnGT|V2W0GQR1XS
NCI-H209 NWPBUWVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLi[plJUUN3ME2yPU45OzZ4IN88US=> NIXJOFNUSU6JRWK=
NBsusSR Mn7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDvbGZYUUN3ME2yPU46QTB2IN88US=> M1TmeXNCVkeHUh?=
NCI-H1304 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTNyLkW3NVYh|ryP M2DoRXNCVkeHUh?=
NB14 NF35PWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXW4NFVbUUN3ME2zNU4xPDR4IN88US=> MWHTRW5ITVJ?
HCC1419 MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTNzLkK0JO69VQ>? MVzTRW5ITVJ?
KG-1 M2OwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTNzLke0Nlkh|ryP MX3TRW5ITVJ?
A2780 NYKzVYtJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrTTWM2OD1|MT64N|U5KM7:TR?= M4Xsb3NCVkeHUh?=
NCI-H28 NVfNPFJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnVc205UUN3ME2zNU46QDZzIN88US=> NYK1cWZ4W0GQR1XS
C2BBe1 MnH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLldXRLUUN3ME2zNk4zPjN2IN88US=> NIfobWVUSU6JRWK=
VA-ES-BJ NULXSYQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTN{LkOxJO69VQ>? NFHhdmNUSU6JRWK=
SBC-5 NXXQNnQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGeweIlKSzVyPUOyMlg2OTFizszN MYPTRW5ITVJ?
OVCAR-4 NELiXIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fLWmlEPTB;M{OuOFg1QCEQvF2= M1HvdHNCVkeHUh?=
COR-L88 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7XUXlIUUN3ME2zOE4xPzRzIN88US=> MXrTRW5ITVJ?
SW954 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTN2LkC3OVIh|ryP MknTV2FPT0WU
COLO-684 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTN2LkO0NFQh|ryP MlXLV2FPT0WU
HCC70 M{LyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPVc253UUN3ME2zOE46PTF2IN88US=> M2W0XHNCVkeHUh?=
NCI-H1770 MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTN2Lkm2NUDPxE1? M{HNbXNCVkeHUh?=
NCI-H1666 MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTN3LkiyOVMh|ryP MXvTRW5ITVJ?
YH-13 NV;rcnpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fxRWlEPTB;M{WuPVIh|ryP MlrPV2FPT0WU
DJM-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnwXHdKSzVyPUO2MlgxPDlizszN NWHtTolFW0GQR1XS
KNS-62 NH36OIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrvTWM2OD1|Nj65OFM5KM7:TR?= NEjsXVRUSU6JRWK=
SK-MEL-30 M1jOeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTYTWM2OD1|Nz64O|M4KM7:TR?= M1r0VHNCVkeHUh?=
SJRH30 NH\VRnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHsN5pKSzVyPUO4Mlc{PDFizszN NYDLZ5VVW0GQR1XS
GP5d MoXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH35cHFKSzVyPUO4Mlg3PTNizszN NYDxU4M4W0GQR1XS
SW1116 NHXhOJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfhZo9KSzVyPUO5MlI5ODVizszN NXLEe|g3W0GQR1XS
COLO-800 Mn34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPNeZNKSzVyPUO5MlM3OzhizszN NEfvOZBUSU6JRWK=
RD M3noVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\GVVZKSzVyPUO5MlUzPThizszN MV7TRW5ITVJ?
NCI-SNU-5 NGr2WYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonqTWM2OD1|OT62PVE3KM7:TR?= M4nJUnNCVkeHUh?=
HuO-3N1 NITnXmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LyXmlEPTB;NECuNVA5KM7:TR?= MVrTRW5ITVJ?
SK-UT-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7CTWM2OD12MD61Olc1KM7:TR?= MoLJV2FPT0WU
SK-MEL-3 MknXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:5RmlEPTB;NECuOVk{OiEQvF2= NH3UOIZUSU6JRWK=
SK-MEL-28 NGjUdWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof4TWM2OD12MD62OFM2KM7:TR?= NVXpUYlwW0GQR1XS
SCC-4 NFHybYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrJTWM2OD12MT6yNVM4KM7:TR?= NFfmTG1USU6JRWK=
no-11 MmrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjSW3VsUUN3ME20NU44OzV2IN88US=> M4rtZnNCVkeHUh?=
HT-144 MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTR{LkC1Olch|ryP MoXUV2FPT0WU
MFM-223 NH3qbJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTR{LkSwNkDPxE1? NV;T[lFmW0GQR1XS
ONS-76 M3jNdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDaZ|dKSzVyPUSyMlgxOThizszN MWrTRW5ITVJ?
ES8 MkDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\pVlRKSzVyPUSzMlM3QThizszN M4XBd3NCVkeHUh?=
T-24 NHLjcnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLwTWM2OD12Mz60N|Y6KM7:TR?= Mkj6V2FPT0WU
GAMG NVXoc3l4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTR|LkS1NVch|ryP NIiwRW9USU6JRWK=
LU-135 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzDTWM2OD12ND6wPVI{KM7:TR?= MnnkV2FPT0WU
HCC1187 M4[0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml75TWM2OD12ND64NlYzKM7:TR?= NX3oeFZiW0GQR1XS
TE-1 M3;EWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nEfmlEPTB;NEWuNVY2PCEQvF2= NHvqW25USU6JRWK=
J-RT3-T3-5 MmjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTR3LkSzNVUh|ryP NIfW[HBUSU6JRWK=
GI-ME-N NVzZN5V{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTR3Lki5OVIh|ryP M3jESHNCVkeHUh?=
D-392MG MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnEcGw4UUN3ME20OU46OjV4IN88US=> NYfYUVZ6W0GQR1XS
KALS-1 NHfm[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTR4LkeyOVch|ryP MnPYV2FPT0WU
MMAC-SF MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TJW2lEPTB;NE[uPVk2OiEQvF2= MoDUV2FPT0WU
HSC-3 MnLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTR5LkO2NFgh|ryP MofCV2FPT0WU
KM-H2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ewcWlEPTB;NEeuOlAxPyEQvF2= MYrTRW5ITVJ?
LoVo NGXRXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPrfYVkUUN3ME20PE4yODB{IN88US=> MkHEV2FPT0WU
NCI-H510A NH\TfJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTR6LkG4O|Eh|ryP NWLPTlRkW0GQR1XS
EW-11 NF;sV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rrNGlEPTB;NEiuNlM1QCEQvF2= M4nhOHNCVkeHUh?=
HCC2998 MmPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnocXhKSzVyPUS4MlYzOzZizszN Mor2V2FPT0WU
J82 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTR6LkeyOFIh|ryP M4DJT3NCVkeHUh?=
ML-2 NWDZUINST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTR7LkS2NFUh|ryP NH;rcpBUSU6JRWK=
NCI-H2030 NXjJXnloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\6TWM2OD12OT63NVE4KM7:TR?= MXrTRW5ITVJ?
NCI-H1792 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTR7Lki1NVgh|ryP NX;2Xlc5W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo試験 Nilotinib reduces collagen deposition and α-SMA expression in CCl4 and BDL-induced fibrosis. Nilotinib could induce HSC undergoing apoptosis, which is correlated with downregulation of bcl-2. [2] Nilotinib attenuates the extent of lung injury and fibrosis. Nilotinib therapy significantly reduces the levels of hydroxyproline on days 14 and 21, which is accompanied by decreased expression levels of transforming growth factor (TGF)-β1 and PDGFRβ. [5] AMN107 prolongs survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolongs survival in imatinib-resistant CML mouse models. [6]

プロトコル(参考用のみ)

細胞アッセイ: [4]
+ 展開
  • 細胞株: Human primary Schwann and schwannoma cells
  • 濃度: 1-10 μM
  • 反応時間: 72 hours
  • 実験の流れ: Human primary Schwann and schwannoma cells are seeded on precoated 96-well plates. Nilotinib is added 40 minutes before stimulation with 100 ng/mL PDGF-DD, and cells are cultured for 72 hours (3 days). Because the half-life of Nilotinib is 18 hours, one-half of the originally added concentrations are added freshly every day. In addition to DAPI staining and determination of the total cell number, the more sensitive and accurate BrdU incorporation method is used to detect proliferating cells. Total cell amount (DAPI) and number of dividing cells (BrdU-positive) are blindly counted using an inverted fluorescent microscope and 200 × magnification. All cells in every well are counted. The total cell number per well differed between various cell batches and is 100–300 cells/well.
    (参考用のみ)
動物実験:[6]
+ 展開
  • 動物モデル: Systemic 32D Bcr-Abl leukemia model in Female BALB/c mice, Bioluminescent Bcr-Abl model of CML in Female NOD-SCID mice and Bone marrow transplant Bcr-Abl model of CML in syngeneic Balb/c recipient mice
  • 製剤: 10% NMP-90% PEG300, PEG300
  • 投薬量: 75 mg/kg, 100 mg/kg
  • 投与方法: Oral administration
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 27 mg/mL (50.98 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
体内 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 3mg/mL

* <1 mg/mlは製品が微弱に溶解する或いは溶解しないことを示します。
* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 529.52
化学式

C28H22F3N7O

CAS No. 641571-10-0
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02973711 Not yet recruiting Leukemia, Chronic Myeloid University of Michigan Cancer Center February 2017 Phase 1|Phase 2
NCT02954978 Recruiting Parkinson Disease|Parkinsons Disease With Dementia Georgetown University January 2017 Phase 2
NCT02947893 Recruiting Alzheimers Disease Georgetown University January 2017 Phase 2
NCT02602314 Not yet recruiting Chronyc Myeloid Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto December 2016 Phase 4
NCT02709083 Recruiting Chronic Myelogenous Leukemia|Chronic Myeloid Leukemia|Leukemia Emory University October 2016 Phase 2
NCT02917720 Not yet recruiting Chronic Myeloid Leukemia European LeukemiaNet|Heidelberg University|Ludwig-Maximilians - University of Munich October 2016 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

Bcr-Abl信号経路図

Bcr-Abl Inhibitors with Unique Features

相関Bcr-Abl製品

Tags: Nilotinib (AMN-107)を買う | Nilotinib (AMN-107) ic50 | Nilotinib (AMN-107)供給者 | Nilotinib (AMN-107)を購入する | Nilotinib (AMN-107)費用 | Nilotinib (AMN-107)生産者 | オーダーNilotinib (AMN-107) | Nilotinib (AMN-107)化学構造 | Nilotinib (AMN-107)分子量 | Nilotinib (AMN-107)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID